<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019222</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021- 0257</org_study_id>
    <nct_id>NCT05019222</nct_id>
  </id_info>
  <brief_title>Comparison of Postoperative QoR-15 Scores Between Sevoflurane and Remimazolam</brief_title>
  <official_title>Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During General Anesthesia in the Cervical Spine Surgery Patients: Sevoflurane vs. Remimazolam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the quality of recovery (QoR)-15 scores according to&#xD;
      the use of maintenance anesthetics in the cervical spine surgery. Total intravenous&#xD;
      anesthesia (TIVA) have been known to help reducing risks of postoperative nausea/vomiting and&#xD;
      malignant hyperthermia. However, it is still not enough to explain which is better between&#xD;
      TIVA or inhalation anesthesia. In particular, there is no study to investigate overall&#xD;
      postoperative functional recovery via QoR-15 in patients receiving TIVA with remimazolam. The&#xD;
      hypothesis of the investigators study is that, in patients with cervical spine surgery, total&#xD;
      intravenous anesthesia based on remimazolam can improve the the quality of recovery compared&#xD;
      to inhalation anesthesia based on sevoflurane.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 26, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between two groups (sevoflurane vs. remimazolam) in QoR-15 scores</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>The difference of scores in the Quality of Recovery (QoR)-15 survey on POD 1 Total 0-150, 0 (minimum), 150 (maximum), Higher scores means better.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Anterior Cervical Discectomy and Fusion (ACDF) Surgery</condition>
  <arm_group>
    <arm_group_label>Arm 1) Sevoflurane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane based inhalation anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2) Remimazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam based total intravenous anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane based inhalation anesthesia</intervention_name>
    <description>Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.</description>
    <arm_group_label>Arm 1) Sevoflurane group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam based total intravenous anesthesia</intervention_name>
    <description>Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.</description>
    <arm_group_label>Arm 2) Remimazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients who aged 20-70 years&#xD;
&#xD;
          -  ASA-PS: 1-3&#xD;
&#xD;
          -  BMI &lt; 30&#xD;
&#xD;
          -  Anterior cervical discectomy and fusion surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tolerance or hypersensitivity to benzodiazepine&#xD;
&#xD;
          -  Dependence or addiction to psychotropic drugs or alcohol&#xD;
&#xD;
          -  Pregnant women, subjects who lack the ability to make decisions and susceptible to&#xD;
             voluntary participation decisions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Myung Hwa Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Hwa Kim</last_name>
      <phone>82-2-2019-3520</phone>
      <email>KMH2050@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Myoung Hwa Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cervical surgery</keyword>
  <keyword>Quality of Recovery</keyword>
  <keyword>Remimazolam</keyword>
  <keyword>sevoflurane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

